The Pharma Data

AUGUST 7, 2020

As the pharma industry stands firm in its commitment to advance the sector to fight Covid-19, news has emerged from the European Commission who intend to streamline the development of therapies using genetically modified organisms to treat Covid-19. Regenerative medicine and advanced therapies thriving despite Covid-19 disruption.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Trials 52

Drug Discovery World

OCTOBER 16, 2023

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

FEBRUARY 28, 2024

CRISPR and brain cancer Meanwhile, elsewhere in the US, another exciting development – using CRISPR as a therapeutic approach – has possibilities for tackling brain cancer. Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers.

Development 64

Development Research Drugs Antibody 64

XTalks

NOVEMBER 6, 2020

The Burnaby, BC-based company developed the oral DNA-based vaccine using its proprietary bacTRL Gene Therapy Platform, which uses genetically modified bifidobacteria as carriers of genetic vaccine elements on a DNA plasmid. BacTRL Gene Therapy Platform. Related: Red Meat Allergy Test Gets FDA Clearance. “We

Clinical Trials 75

Clinical Trials Clinical Trials Vaccination Vaccine 75

Drug Discovery World

OCTOBER 4, 2022

Taking place at the ExCel in London from 4-5 October, ELRIG Drug Discovery 2022 is set to provide visitors with access to the latest trends, technologies and expertise driving the life sciences sector. . Cell and gene therapies. In 2021, levels of investment hit an all-time high at $22.7 billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — Caris Life Sciences® , a leading innovator in molecular science focused on fulfilling the promise of precision medicine, announced today that Winship Cancer Institute of Emory University (Winship) has joined Caris’ Precision Oncology Alliance (The Alliance/POA). .

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Pharmaceutical Technology

DECEMBER 22, 2022

The company has partnered with life sciences-focused investors Sixth Street and Royalty Pharma with an aim to bring substantial non-dilutive, low-cost capital to boost innovation and growth. This genetic-led approach will also aid in expediting the approval of new treatments.

Insulin 130

Insulin Production Development Genetics 130

XTalks

AUGUST 15, 2023

Approximately 10 to 15 percent of patients with mCRPC have alterations in the BRCA gene — this subset of patients is likely to have aggressive disease, poor outcomes and a shorter survival time, according to information in a press release from Johnson & Johnson announcing Akeega’s FDA approval.

FDA Approval 52

FDA Approval Gene Hormones Licensing 52

The Pharma Data

JANUARY 20, 2021

Franchi is an experienced board member, finance executive and operational leader with more than three decades of experience in the life sciences industry. “I am honored to join the Dynacure Board and am eager to help the team advance its pipeline through development.” Franchi to its Board of Directors. ” Ms.

Life Science 52

Life Science Development Genetics Production 52

Delveinsight

AUGUST 4, 2021

Similarly, genetics, immune response, and environmental factors also influence the occurrence of Neurological Conditions. With the advancement in technology, today diagnostics testing such as neurological examination, brain scans, genetic screening, and other tests are available to examine the occurrence of Neurological Conditions.

Marketing 98

Marketing Genetics Development Clinical Development 98

pharmaphorum

DECEMBER 23, 2020

It has been a year dominated by the pandemic and many life sciences research projects were put on hold as big pharma turned its attention to vaccines and therapies. But there was some considerable progress in other fields of medicine even though research efforts were diverted away, reports Richard Staines.

Marketing 77

Marketing Gene Silencing Gene Drugs 77

The Pharma Data

MARCH 16, 2021

“The Lieber Institute has a long-standing effort exploring centrally acting COMT inhibitors as part of its mission to understand the genetic and molecular mechanisms of schizophrenia and related brain disorders,” said Daniel R. Weinberger, M.D., LIBD CEO & Director. “We Our significant investment of almost 3.5

Development 52

Development Contract Manufacturing Licensing Licensing 52

The Pharma Data

DECEMBER 17, 2020

Cadavid will be responsible for the strategy, direction and execution of the company’s clinical development programs. Prior to Fulcrum, Cadavid held several leadership positions at Biogen, including Senior Medical Director of the multiple sclerosis clinical development group. based Rinri Therapeutics.

Development 52

Development Gene Therapy Engineer Life Science 52

pharmaphorum

JANUARY 27, 2023

Developing medicines – for people living with disease Dr Mullen’s current role involves providing medical monitoring support, as well as safety, pharmacovigilance, scientific, and medical advice across a range of client projects, including advanced therapies and orphan drugs. I still feel that it is very important,” Dr Mullen said. “We’ve

Clinical Trials 103

Clinical Trials Clinical Trials Trials Development 103

XTalks

MARCH 13, 2023

The US Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) held a recent town hall where three experts from the regulator provided guidance on how to design and conduct gene therapy clinical trials for rare diseases. It’s a very exciting time in gene therapy.

Gene Therapy 52

Gene Therapy Clinical Trials Clinical Trials Gene 52

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

pharmaphorum

SEPTEMBER 12, 2022

Everyone’s genetic makeup differs, and each person’s cancer experience is unique to them – how cancer develops, how fast it spreads, which drugs it responds to, and more. Cancer cells and tumours behave differently than normal cells and have changes in their genes that make them different from an individual’s normal cells.

Genome 104

Genome Genomics Clinical Trials Clinical Trials 104

pharmaphorum

OCTOBER 26, 2022

For example, at the SSIEM Annual Symposium earlier this month, the company shared data on a new candidate for the treatment of Fabry disease, a rare genetic blood disorder. We design our clinical development strategy and the trials with this aim in mind.”. In 2021, he was awarded the Champion of Hope award from Global Genes.

Development 84

Development Trials Marketing Life Science 84

XTalks

APRIL 12, 2021

Read on to learn about the latest updates from Parkinson’s biotech companies Prevail Therapeutics, Axovant Gene Therapies, Voyager Therapeutics, Inflazome, Denali Therapeutics and Neuropore Therapies, and also find out about some emerging players in the Parkinson’s disease space. Axovant Gene Therapies. Prevail Therapeutics.

Gene Therapy 96

Gene Therapy Gene Trials Development 96

Drug Discovery World

MARCH 6, 2024

The development of effective new disease-modifying treatments in neurodegenerative and neuropsychiatric disorders has been hindered by their inherent genetic complexity, environmental influences, and clinical variability. This is comparatively easier to accomplish in these diseases because they are relatively monogenic.

Genome 64

Genome Genomics Clinical Trials Clinical Trials 64

XTalks

NOVEMBER 20, 2023

The newly approved Truqap and Faslodex combo is restricted to patients with a genetic alteration in one or more of the following PI3K/AKT pathway genes: PIK3CA , AKT1 or PTEN. Alterations in genes in the PI3K family lead to aberrant activation of the pathway to enhance cancer cell survival.

HR 98

HR FDA Approval Gene Trials 98

Delveinsight

DECEMBER 8, 2020

KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-Oncology market. based gene therapy company AskBio by Bayer made headlines.

Licensing 52

Licensing Licensing Gene Therapy Antibody 52

Drug Discovery World

OCTOBER 30, 2023

By analysing additional clinical and phenotypic data from the University of Oxford’s Oxegene dataset we hope to both replicate those findings and provide greater insights into the underlying genetic factors relating to specific phenotypes and symptoms that are seen in the disease.

Genome 72

Genome Genomics Genotype Clinical Trials 72

XTalks

JUNE 9, 2022

What happens when the liver is unable to process bad cholesterol due to genetic factors? It is one of the common genetic causes of premature coronary heart disease. When a child born from parents with FH genes, inherits one FH gene from each parent, they might develop homozygous familial hypercholesterolemia (HoFH).

Trials 52

Trials Antibody Genetics Gene 52

The Pharma Data

AUGUST 15, 2021

Vivet Therapeutics (“Vivet”), a clinical-stage biotechnology company, and Pfizer Inc. The FDA’s Fast Track program is designed to facilitate the development, and expedite the review of, novel potential therapies that are designed to treat serious conditions and fill unmet medical need. NYSE: PFE) today announced the U.S. About VTX-801.

Gene Therapy 52

Gene Therapy Gene Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 15, 2023

Genetically modified T cells stimulated with IL2 are now administered as cell therapy for multiple cancer cell types with beneficial results 3,4. Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6.

Research 52

Research In-Vitro In-Vivo Development 52

XTalks

DECEMBER 24, 2020

The pandemic propelled the life science and healthcare sectors onto center stage, and they rose to the occasion against the most unprecedented health challenge in recent times. While COVID-19 has undoubtedly been the biggest story in the life science industry in 2020, it was a busy and positive year in many other areas.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

OCTOBER 15, 2020

Mukul Agarwal, former vice president of Corporate Development, at Forty Seven, Inc., Axovant – Kristin Vuori was named to the board of directors at Axovant Gene Therapies Ltd. Nielsen, the primary inventor of peptide nucleic acid (PNA) technology, brings extensive experience in genetic medicine to the company.

In-Vivo 52

In-Vivo Business Development Manufacturing Development 52

Pharmaceutical Technology

MAY 26, 2023

Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines. As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA.

DNA 130

DNA Manufacturing Gene Therapy Gene 130

XTalks

SEPTEMBER 14, 2020

Unlike other candidate vaccines, CoronaVac is an inactivated whole virus vaccine developed through the same process as has long been used to make influenza vaccines, among many others. Several laboratories have already shown that they can detect genetic material from the virus in wastewater.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92